Yes, Ehlers-Danlos syndrome (EDS) is genetic. Nearly all recognized types are caused by mutations in specific genes that affect how the body builds or processes collagen, the protein that gives structure and strength to skin, blood vessels, joints, and organs. There are currently 13 recognized subtypes of EDS, each linked to mutations in different genes, and the condition can be inherited from a parent or arise spontaneously as a new mutation.
How EDS Is Inherited
EDS follows two main inheritance patterns depending on the subtype. Several of the more common forms, including classical EDS and vascular EDS, are autosomal dominant. This means only one copy of the mutated gene (from one parent) is enough to cause the condition. If you have an autosomal dominant form, each of your children has a 50% chance of inheriting it.
Other subtypes are autosomal recessive, meaning a child must inherit a mutated copy from both parents to develop the condition. These include kyphoscoliotic EDS, dermatosparaxis EDS, cardiac-valvular EDS, and classical-like EDS. Parents who each carry one copy of a recessive mutation typically show no symptoms themselves, but each pregnancy carries a 25% chance of the child being affected.
Not Every Case Is Inherited From a Parent
A significant number of EDS cases appear in families with no prior history of the condition. About half of people diagnosed with classical EDS have no affected parent. Their condition results from a de novo mutation, a spontaneous genetic change that happens during early development rather than being passed down. The pattern is similar in vascular EDS: a study of 177 people with vEDS found that roughly 51% had no family history, pointing to a de novo mutation. In rare cases (2 to 3%), a parent carries the mutation in only some of their cells, a phenomenon called mosaicism, which can make family history misleading.
What These Mutations Do to Collagen
Collagen is built from long protein chains that wind together into a tight triple-helix structure, somewhat like three ropes braided together. Each chain is made of about 300 repeating units, and the structure depends on a specific amino acid (glycine) appearing at every third position. Most disease-causing mutations swap out one of these glycine building blocks, which disrupts the helix and weakens the final collagen fiber.
The consequences cascade from there. Mutated collagen chains often fold incorrectly and get stuck inside the cell rather than being exported to build tissue. This creates stress within the cell, which can reduce cell growth, trigger cell death, or simply lower the total amount of functional collagen in the tissue. The result is connective tissue that stretches too easily, tears more readily, or fails to provide the structural support that skin, joints, and blood vessels need.
Genes Linked to Each Major Subtype
Different subtypes involve different collagen genes or genes that help process collagen after it’s made:
- Classical EDS: Mutations in genes that produce type V collagen, which helps regulate the diameter of collagen fibers in skin and tendons.
- Vascular EDS: Mutations in the gene for type III collagen, which provides strength to blood vessels and hollow organs. Genetic testing identifies the causative mutation in about 95% of clinically diagnosed cases.
- Arthrochalasia EDS: Mutations in genes for type I collagen, the most abundant collagen in the body, found in bone, skin, and tendons.
- Kyphoscoliotic EDS: Mutations in genes that modify collagen after it’s produced, affecting how collagen chains cross-link and stabilize.
- Dermatosparaxis EDS: Mutations in a gene responsible for trimming collagen into its final functional form.
In total, at least 14 genes have been identified across the various subtypes, and genetic testing panels can screen for mutations in all of them simultaneously.
The Exception: Hypermobile EDS
Hypermobile EDS (hEDS) is the most common subtype and the one major exception to the clear gene-to-disease picture. No single causative gene has been identified, and diagnosis remains based on clinical criteria rather than genetic testing. Research published in 2025 found the first evidence that common genetic variants, rather than a single gene mutation, contribute to hEDS risk. One significant region was identified near a gene involved in immune and nervous system signaling on chromosome 2. This supports a model where hEDS arises from the combined effects of multiple genes influencing connective tissue, immune function, and nervous system regulation, rather than one straightforward mutation.
Because of this, hEDS does appear to run in families, but the inheritance pattern is less predictable than in other subtypes. You can’t currently confirm or rule out hEDS with a genetic test.
Vascular EDS Carries the Highest Risk
Among all subtypes, vascular EDS (vEDS) is the most medically serious. The loss of functional type III collagen weakens arterial walls and the walls of the intestines and uterus. Life-threatening complications, including spontaneous arterial tears, aneurysms, and bowel perforations, often begin in early adulthood. The median life expectancy for people with vEDS is 51 years. Because the stakes are high and the mutation is identifiable in the vast majority of cases, genetic testing is particularly important for anyone with a family history of vEDS or unexplained arterial events at a young age.
Genetic Testing and Family Planning
For most EDS subtypes other than hEDS, genetic testing can confirm a diagnosis and identify the exact mutation involved. Testing typically uses a panel that screens multiple EDS-related genes at once. Knowing your specific mutation matters not just for your own care but for understanding the risk to future children.
If you have a known EDS mutation and are considering having children, preimplantation genetic testing is available. This process works alongside IVF: embryos are created, then a small number of cells are removed and tested for the specific mutation before the embryo is transferred. A custom test must be developed for each couple, which can take several months, so early planning helps. Prenatal testing during pregnancy is also an option for known mutations.
The current classification system for EDS dates to 2017, and an updated version is expected to be published in late 2026 and early 2027. These updates may refine diagnostic criteria and incorporate new genetic findings, particularly for subtypes like hEDS where the genetic picture is still emerging.